6 news items
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)
BLRX
30 May 24
collaboration partners will be able to execute on collaboration goals in a timely manner; whether the clinical trial results for APHEXDA will be predictive
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
BLRX
28 May 24
procedures performed - on track to reach stated goal of ~35% by end of Q2
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
BLRX
24 May 24
on collaboration goals in a timely manner; whether the clinical trial results for APHEXDA will be predictive of real-world results; BioLineRx's receipt
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
BLRX
17 May 24
to execute on collaboration goals in a timely manner; whether the clinical trial results for APHEXDA will be predictive of real-world results
BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
BLRX
6 May 24
collaboration partners will be able to execute on collaboration goals in a timely manner; whether the clinical trial results for APHEXDA will be predictive
37m2wlgdqiewxb0bxlsc1qnol2v4w53d5q bfdbbaa2gmi6m5pij712
BLRX
17 Apr 24
preclinical studies or clinical trials; whether BioLineRx's collaboration partners will be able to execute on collaboration goals in a timely manner
- Prev
- 1
- Next